RecruitingPhase 2

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

France20 participantsStarted 2024-11-10

Plain-language summary

The purpose of this project is to study the survival of patients until Haematopoietic Stem Cell Transplantation following the use of Ruxolitinib as first-line treatment associated to corticosteroids in primary HLH.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Confirmed genetic diagnosis of a condition predisposing to primary HLH (see table 1 and table 2) or abnormal expression of perforin, MUNC13-4, SAP or XIAP in FACS and/or positive family history OR
✓. Presence of at least 5 of the 8 following HLH diagnostic criteria:

What they're measuring

Survival until HSCT

Timeframe: Day 0 until HSCT, up to 8 weeks

Trial details

NCT IDNCT05762640

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-05

Contact for this trial

Despina MOSHOUS, MD, PhD

01 44 49 48 23 despina.moshous@aphp.fr

View on ClinicalTrials.gov More Haemophagocytic Lymphohistiocytosis trials